NATERA INC (Common Stock) – ticker 45E (NTRA)
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.3 per share a year ago.
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
A high-growth gem is the largest holding in Stanley Druckenmiller's firm's fund.
Natera: The Clues In Q1 Earnings
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue.
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.56 per share a year ago.
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript
Natera, Inc. (NASDAQ:NTRA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Alexey Aleshin - GM Oncology, CMO Solomon Moshkevich - President, Clinical Diagnostics John Fesko - President and Chief Business Officer Conference Call Participants Doug Schenkel - Wolfe Research Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Baird Daniel Brennan - TD Cowen Dan Leonard - UBS Subbu Nambi - Guggenheim Operator Welcome everyone to Natera's 2024 Fourth Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates
Natera (NTRA) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.64 per share a year ago.
Natera (NTRA) Recently Broke Out Above the 20-Day Moving Average
From a technical perspective, Natera (NTRA) is looking like an interesting pick, as it just reached a key level of support. NTRA recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering diverse investment opportunities and encouraging discussion among investors. Ready Capital Corporation's new senior notes offer a 9% yield but are seen to face risks due to recent dividend cuts and negative earnings-to-debt ratios. Alex Pitti sees AVITA Medical showing strong growth potential with new product launches and increased market opportunities, making it a compelling long-term investment.
Natera: Poised For A Great Future But I'd Wait For A Pullback
Natera, a leader in cfDNA testing, has shown impressive growth and is nearing profitability, but its current valuation appears overextended. The company's competitive landscape is intense, with rivals like Guardant Health and Quest Diagnostics, and ongoing litigation posing potential risks. Natera's revenue growth is driven by its oncology segment, particularly the Signatera test, but future growth may moderate as it nears its TAM.
